Keralty Hospital Miami | Keralty Research Center

Research site

Location

2500SW 75 Avenue, Miami, Florida, United States of America

Site insights

Top conditions

Top treatments

RDV

Palmitoylethanolamide

Niclosamide

TV-44749

Pomotrelvir

PEA

PBI-0451

APL-9

NP-120

Baricitinib

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Contact this site

Maria T Bertoli

Verified by this site

Active trials

4 of 13 total trials

A Randomized, Double-Blind, Placebo-Controlled Study With an Open-Label, Long-Term Safety Phase to Evaluate the Efficacy and Safety of TV-44749 in Adults With Schizophrenia (SOLARIS)

The primary objective of this study is to evaluate the efficacy of TV-44749 in adult participants with schizophrenia.A key secondary objective is to...

Active, not recruiting

Schizophrenia

Drug: TV-44749 - Dose level 3

Drug: Placebo

A Study Comparing Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination CHF 5993 With the Fixed Dose Dual Combination CHF 1535 in Subjects With COPD (TRITON)

The purpose of this study is to compare CHF 5993 with CHF 1535 in improving lung function, reducing moderate and severe COPD exacerbations, and other...

Enrolling

COPD

COPD Exacerbation

Drug: Beclomethasone Dipropionate

Drug: Formoterol Fumarate

A Study to Evaluate Safety and Tolerability of CVL-231 (Emraclidine) in Adult Participants With Schizophrenia

The primary purpose of this study is to assess the long-term safety and tolerability of oral emraclidine in adult participants with schizophrenia.

Enrolling

Schizophrenia

Drug: CVL-231 30 mg

Bacteriophage Therapy TP-102 in Patients With Diabetic Foot Infection (REVERSE2)

TP-102 is a novel bacteriophage cocktail comprised of 5 (five) lytic bacteriophages against Staphylococcus aureus, Pseudomonas aeruginosa, and Acinet...

Enrolling

Diabetic Foot Infection

Biological: TP-102

Other: Placebo